Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
69 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Insulin Resistance - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Insulin Resistance - Pipeline Review, H1 2015', provides an overview of the Insulin Resistance's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Insulin Resistance, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Insulin Resistance and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Insulin Resistance - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Insulin Resistance and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Insulin Resistance products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Insulin Resistance pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Insulin Resistance - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Insulin Resistance pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Insulin Resistance Overview 8 Therapeutics Development 9 Pipeline Products for Insulin Resistance - Overview 9 Pipeline Products for Insulin Resistance - Comparative Analysis 10 Insulin Resistance - Therapeutics under Development by Companies 11 Insulin Resistance - Therapeutics under Investigation by Universities/Institutes 13 Insulin Resistance - Pipeline Products Glance 14 Clinical Stage Products 14 Early Stage Products 15 Insulin Resistance - Products under Development by Companies 16 Insulin Resistance - Products under Investigation by Universities/Institutes 17 Insulin Resistance - Companies Involved in Therapeutics Development 18 AUS Bio Limited 18 Genfit SA 19 GlaxoSmithKline plc 20 Hadasit Medical Research Services & Development Ltd 21 Mertiva AB 22 Mochida Pharmaceutical Co., Ltd. 23 Novartis AG 24 Prometheon Pharma, LLC 25 Sanofi 26 Thetis Pharmaceuticals LLC 27 Insulin Resistance - Therapeutics Assessment 28 Assessment by Monotherapy Products 28 Assessment by Target 29 Assessment by Mechanism of Action 31 Assessment by Route of Administration 33 Assessment by Molecule Type 35 Drug Profiles 37 6860766 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Antisense Oligonucleotides to Target ABHD6 for Gastrointestinal and Metabolic Disorders - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 BVS-857 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Drug to Inhibit Elovl-6 for Metabolic Diseases And Cardiovascular - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Drugs to Agonize GABA Receptor for Diabetes and Rheumatoid Arthritis - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Drugs to Inhibit TRIP-Br2 for Metabolic Disorders - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Englerin A - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 GFT-505 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 MD-960 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Oligonucleotide to Inhibit IRAK-3 for Cardiovascular and Metabolic Disorders - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 PEG-Catalase - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Peptide for Obesity and Insulin Resistance - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 SAR-088 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 SERX-1 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Small Molecule for Hypertension and Insulin Resistance - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Small Molecule to Antagonize TRPV4 for Metabolic Disorders and Inflammation - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Small Molecule to Target AMPD2 for Hypertension and Metabolic Disorders - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Synthetic Peptide to Inhibit Protein Kinase C for Type 2 Diabetes and Insulin Resistance - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 TP-113 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Insulin Resistance - Recent Pipeline Updates 60 Insulin Resistance - Dormant Projects 66 Insulin Resistance - Product Development Milestones 67 Featured News & Press Releases 67 Oct 19, 2011: Genfit Announces Hospital-Based Clinical Study Demonstrates Action Of GFT505 On Liver 67 Appendix 68 Methodology 68 Coverage 68 Secondary Research 68 Primary Research 68 Expert Panel Validation 68 Contact Us 69 Disclaimer 69
List of Tables Number of Products under Development for Insulin Resistance, H1 2015 9 Number of Products under Development for Insulin Resistance - Comparative Analysis, H1 2015 10 Number of Products under Development by Companies, H1 2015 12 Number of Products under Investigation by Universities/Institutes, H1 2015 13 Comparative Analysis by Clinical Stage Development, H1 2015 14 Comparative Analysis by Early Stage Development, H1 2015 15 Products under Development by Companies, H1 2015 16 Products under Investigation by Universities/Institutes, H1 2015 17 Insulin Resistance - Pipeline by AUS Bio Limited, H1 2015 18 Insulin Resistance - Pipeline by Genfit SA, H1 2015 19 Insulin Resistance - Pipeline by GlaxoSmithKline plc, H1 2015 20 Insulin Resistance - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2015 21 Insulin Resistance - Pipeline by Mertiva AB, H1 2015 22 Insulin Resistance - Pipeline by Mochida Pharmaceutical Co., Ltd., H1 2015 23 Insulin Resistance - Pipeline by Novartis AG, H1 2015 24 Insulin Resistance - Pipeline by Prometheon Pharma, LLC, H1 2015 25 Insulin Resistance - Pipeline by Sanofi, H1 2015 26 Insulin Resistance - Pipeline by Thetis Pharmaceuticals LLC, H1 2015 27 Assessment by Monotherapy Products, H1 2015 28 Number of Products by Stage and Target, H1 2015 30 Number of Products by Stage and Mechanism of Action, H1 2015 32 Number of Products by Stage and Route of Administration, H1 2015 34 Number of Products by Stage and Molecule Type, H1 2015 36 Insulin Resistance Therapeutics - Recent Pipeline Updates, H1 2015 60 Insulin Resistance - Dormant Projects, H1 2015 66
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
